Stock Events

Stock Events

CNBX Pharmaceuticals 

€3.88
0
+€0.00+0% Monday 20:00

Statistics

Day High
3.88
Day Low
3.4
52W High
3.88
52W Low
3.4
Volume
19
Avg. Volume
0
Mkt Cap
5.72B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-280,760.1Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8C80.MU. It's not an investment recommendation.
Apple
4
AAPL
Tesla
3
TSLA
AMC Entertainment
3
AMC
Canopy Growth
3
CGC

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap211.01M
Corbus Pharmaceuticals Holdings, Inc. focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases, competing with CNBX's research in cannabinoid-based therapeutics for similar conditions.
Tilray Brands
TLRY
Mkt Cap631.5M
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, posing competition to CNBX's efforts in medical cannabis research and product development.
Canopy Growth
CGC
Mkt Cap449.07M
Canopy Growth Corporation is a world-leading diversified cannabis and cannabinoid-based consumer product company, competing with CNBX in the development and commercialization of cannabis and hemp-based products.
Aurora Cannabis
ACB
Mkt Cap253.87M
Aurora Cannabis is engaged in the production and distribution of medical cannabis, directly competing with CNBX in the medical cannabis market.

About

CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.
Show more...
CEO
Eyal Barad
Employees
1
Country
United States
ISIN
US13764M2098

Listings

MU
DE
8C80.MU
MU
DE
8C8.MU
STU
DE
8C8.STU
OTC Link
US
CNBX

0 Comments

Share your thoughts

FAQ

What is CNBX Pharmaceuticals stock price today?▼
The current price of 8C80.MU is €3.88 EUR — it has increased by +0% in the past 24 hours. Watch CNBX Pharmaceuticals stock price performance more closely on the chart.
What is CNBX Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange CNBX Pharmaceuticals stocks are traded under the ticker 8C80.MU.
Is CNBX Pharmaceuticals stock price growing?▼
8C80.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year CNBX Pharmaceuticals has showed a +0% increase.
What is CNBX Pharmaceuticals market cap?▼
Today CNBX Pharmaceuticals has the market capitalization of 5.72B
What is CNBX Pharmaceuticals revenue for the last year?▼
CNBX Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is CNBX Pharmaceuticals net income for the last year?▼
8C80.MU net income for the last year is -280,760.1 EUR.
How many employees does CNBX Pharmaceuticals have?▼
As of September 04, 2026, the company has 1 employees.
In which sector is CNBX Pharmaceuticals located?▼
CNBX Pharmaceuticals operates in the Health & Wellness sector.
When did CNBX Pharmaceuticals complete a stock split?▼
The last stock split for CNBX Pharmaceuticals was on May 12, 2022 with a ratio of 1:120.
Where is CNBX Pharmaceuticals headquartered?▼
CNBX Pharmaceuticals is headquartered in Bethesda, United States.